Webinars and Sponsored Roundtables — Register Now
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Sysmex Corp.
| Company | Sysmex Corp. |
|---|---|
| Name of analyzer | XN-330, XN-430, XN-530 |
| Contact | Madelaine Dintelman |
| City, State | Lincolnshire, IL |
| Phone | 888-879-7639 |
| Website | |
| Analyzer application | diagnostic use |
| Dimensions of analyzer (H × W × | XN-530: 17.7 × 17.7 × 26 in./varies by configuration |
| Country where analyzer was | Japan/Japan |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S.* | 2017/>1, 500 |
| First year analyzer sold outside | 2015/— |
| Foreign locations where company | — |
| Human languages (other than | — |
| Analyzer list price | — (slide maker stainer sold separately) |
| • Analyzer acquisition options | purchase, trade in, lease, cost per reportable contract |
| Training included with purchase/Total time for basic training per operator | 2 min. daily; 15 min. weekly |
| • Follow-up training available | yes (no extra charge) |
| Parameters that analyzer tests and reports | %&# eosinophils, %&# immature granulocytes, %&# lymphocytes, %&# monocytes, %&# neutrophils, %&# basophils, Hb, Hct, MCH, MCHC, MCV, PLT, RBC, WBC |
| Types of testing FDA cleared or approved for analyzer | blood count analysis, body fluid analysis |
| Types of body fluids FDA cleared or approved for analysis on analyzer | — |
| Analytical measurement range for body fluid | — |
| Precision for body fluid | — |
| Accuracy for body fluid | — |
| Automated differential performed for body fluids | — |
| Tests available for research use only | — |
| Differential methods used | fluorescent flow cytometry |
| Analytical measurement range: • WBC count/RBC count | WBC: 0.04–440.00 × 103/μL/RBC: 0.02–8.60 × 106/μL |
| Precision: • WBC count/RBC count | WBC: <3.0%/RBC: <1.5% |
| Accuracy: • WBC count/RBC count | — |
| Interfering substances: • WBC/RBC | no significant interference up to 39.4 mg/dL for bilirubin C, 37.4 mg/dL for bilirubin F, 996 mg/dL for hemolysis, 30.320 optical density for intralipid, 2, 880 OD for chyle/no significant interference up to 39.4 mg/dL for bilirubin C, 37.4 mg/dL for bilirubin F, 996 mg/dL for hemolysis, 30.320 optical density for intralipid, 2, 880 OD for chyle |
| • Hemoglobin/Platelets | no significant interference up to 39.4 mg/dL for bilirubin C, 37.4 mg/dL for bilirubin F, 199 mg/dL for hemolysis/no significant interference up to 39.4 mg/dL for bilirubin C, 37.4 mg/dL for bilirubin F, 996 mg/dL for hemolysis, 30.320 optical density for intralipid, 2, 880 OD for chyle |
| • Hematocrit/Reticulocytes | no significant interference up to 39.4 mg/dL for bilirubin C, 37.4 mg/dL for bilirubin F, 996 mg/dL for hemolysis, 30.320 optical density for intralipid, 2, 880 OD for chyle/— |
| • Automated differential | — |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | 60/60 |
| • Max. No. of slides processed per hour if stainer included | — |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | none |
| Min. specimen volume open mode/Closed mode/Microsample capability | 25 µL/25 µL/yes |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | demographics, results, flags/10, 000 results |
| Analyzer performs delta checks | yes |
| Parameters for which flags may appear | flags for all reportable parameters deemed abnormal per lab’s protocol, more |
| Analyzer recognizes and holds test results | yes, for potential test rerun |
| Scattergram display uses cell-specific color | yes |
| Histogram display uses color with thresholds | yes |
| LIS interface formats supported | ASTM 1381, ASTM 1394-97 |
| • Middleware interface | yes (can use company’s middleware or Data Innovations) |
| • Information transferred to LIS via middleware or LIS interface | numeric results, flagged results, histograms, scatterplots, patient demographics, patient orders, host query for patient demographics and orders |
| Analyzer transmits LOINC codes for results to LIS or middleware | yes |
| Lab automation system or workcells to which analyzer has a direct interface | none |
| Barcode symbologies read on specimen tube | Codabar, Code 39, Code 128, ITF, NW-7, ISBT 128, JAN/EAN/UPC |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | yes |
| No. of onboard reagents required for standard specimen analysis | 4 |
| • Reagents ready to use/Reagent tracking method | yes/RFID, barcode reader |
| Onboard diagnostics for troubleshooting | yes |
| • Manufacturer can perform diagnostics via remote access | yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | one-year warranty/— |
| Notes | †also marketed by McKesson, Henry Schein |